药物发现,开发和制造 499条(本栏目收费,不能显示细节,电话15274084725)
RADIOPHARMACEUTICALS AND MEDICAL
IMAGING: DEVELOPMENT OF
RADIOIMMUMOCONJUGATES FOR
RADIOIMMUNOIMAGING AND
RADIOIMMUNOTHERAPY OF MALIGNANT DISEASES 14478
THERAPEUTIC DRUG DEVELOPMENT FOR
KIDNEY DISEASES 14500
TARGETING CHEMOKINES AND ANGIOGENESIS
IN RHEUMATOID ARTHRITIS * 14526
DEVELOPMENT OF THERAPEUTIC AGENTS:
METHODS AND APPROACHES IN THE
DEVELOPMENT OF VACCINES AGAINST
PROTOZOAN PARASITES 14548
DEVELOPMENT OF PHOSPHODIESTERASE 4
INHIBITORS FOR ALLERGIC AND NONALLERGIC
INFLAMMATORY DISEASES OF THE AIRWAYS 14574
DRUG INTERACTIONS FOR
THERAPEUTIC PROTEINS:
A JOURNEY JUST BEGINNING 14592
PHARMACOKINETIC AND
PHARMACODYNAMIC-BASED DRUG
INTERACTIONS FOR THERAPEUTIC
PROTEINS 14596
DRUG INTERACTION ASSESSMENT
STRATEGIES: SMALL MOLECULES
VERSUS THERAPEUTIC PROTEINS 14630
MODEL-INDEPENDENTAND MODELBASED
METHODS TO ASSESS
DRUG–DRUG INTERACTIONS FOR
THERAPEUTIC PROTEINS 14654
UTILITY OF IN VITRO METHODS
IN DRUG–DRUG INTERACTION
ASSESSMENTAND PREDICTION
FOR THERAPEUTIC BIOLOGICS 14664
USE OF ANIMAL MODELS FOR
PROJECTION OF CLINICAL
DRUG–DRUG INTERACTIONS FOR
THERAPEUTIC PROTEINS 14694
THE COCKTAIL APPROACH AND ITS
UTILITY IN DRUG–DRUG INTERACTION
ASSESSMENTS FOR THERAPEUTIC
PROTEINS 14702
LOGISTIC CONSIDERATIONS IN STUDY
DESIGN FOR BIOLOGIC DRUG–DRUG
INTERACTION ASSESSMENTS 14710
STATISTICAL CONSIDERATIONS
IN ASSESSING DRUG–DRUG
INTERACTIONS FOR THERAPEUTIC
BIOLOGICS 14730
SCIENTIFIC PERSPECTIVES ON
THERAPEUTIC PROTEIN DRUG–DRUG
INTERACTION ASSESSMENTS
14746
DISEASE–DRUG–DRUG INTERACTION
ASSESSMENTS FOR TOCILIZUMAB—A
MONOCLONAL ANTIBODY AGAINST
INTERLEUKIN-6 RECEPTOR TO
TREAT PATIENTS WITH
RHEUMATOID ARTHRITIS 14782
DRUG–DRUG INTERACTIONS FOR ETANERCEPT—A FUSION PROTEIN 14798
DRUG INTERACTIONS OF CYTOKINES
AND ANTICYTOKINE THERAPEUTIC
PROTEINS 14806
DRUG INTERACTIONS FOR GROWTH
FACTORS AND HORMONES 14830
DRUG–DRUG INTERACTIONS FOR
NUCLEIC ACID-BASED DERIVATIVES 14848
MONOGRAPHS FOR DRUG-DRUG
INTERACTIONS OF THERAPEUTICS
BIOLOGICS 14866
TUMOR-TARGETED
NANOPARTICLES: STATE-OF-THEART
AND REMAINING CHALLENGES 14942
APPLICATIONS OF LIGANDENGINEERED
NANOMEDICINES 14962
LIPID NANOPARTICLES FOR THE
DELIVERY OF NUCLEIC ACIDS 14992
PHOTOSENSITIVE LIPOSOMES
AS POTENTIAL TARGETED
THERAPEUTIC AGENTS 15022
MULTIFUNCTIONAL DENDRITIC
NANOCARRIERS: THE
ARCHITECTURE AND APPLICATIONS
IN TARGETED DRUG DELIVERY 15042
CHITOSAN-BASED NANOPARTICLES
FOR BIOMEDICAL APPLICATIONS 15070
POLYMER–DRUG NANOCONJUGATES 15092
NANOCRYSTALS PRODUCTION,
CHARACTERIZATION, AND
APPLICATION FOR CANCER
THERAPY 15124